Brain Injury Blood Test Breakthrough?

A lab test for CNS-specific proteins could cut the number of unnecessary brain scans

An international study claims that a simple blood test can accurately predict the presence and the severity of traumatic brain injury (TBI). Not only would the availability of such a test in the clinical lab reduce the costs of unnecessary radiological examinations, but it would also allow a quicker patient categorization and provide valuable support for treatment decision-making.

The rationale behind the test is this: glial fibrillary acidic protein breakdown products (GFAP-BDP) are proteins found in the central nervous system (CNS), which can be detected in the serum using sandwich ELISA. These proteins are known to be associated with certain neurological disorders, including TBI. So an international team, headed by Paul McMahon of the University of Pittsburgh Medical Center, US, set about validating the use of this test in the diagnosis of intracranial injury in a broad population of patients with a positive clinical screen for head injury. To do this, blood samples were analyzed in multiple centers, in over 200 patients aged 16–93 who were being treated for suspected TBI (1). Blood was drawn and tested for the GFAP-BDP biomarker within 24 hours of the patients presenting at a clinic, alongside CT scans. Patients were also offered a follow-up MRI within two weeks of the original injury. The results were encouraging: elevated GFAP-BDP was significantly associated with the presence of visible TBI on CT scans, and the severity of injury. The test provided an advantage over clinical screening alone, preventing unnecessary scans by 12–30 percent, and predicted brain pathology on CT scan with an accuracy of 81 percent, higher than that of standard clinical predictors, such as pupillary response and Glasgow Coma Scale score. Radiography is a central part of diagnosing brain injury, but scans can be expensive, and pose risks to the patient. The study authors are hopeful the test could become a useful addition to methods of neurological examination, and believe that “early measurement of GFAP-BDP can contribute to more accurate diagnosis and triage of TBI patients, decreasing the number of unnecessary CT scans and allowing more tailored management of the brain injury.”

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

I have read and understand the Privacy Notice*

Subscribe

References

1. PJ McMahon, et al., “Measurement of the glial fibrillary acidic protein and its breakdown products GFAP-BDP biomarker for the detection of traumatic brain injury compared to computed tomography and magnetic resonance imaging”, J Neurotrauma, 32, 527–533, (2015). PMID: 25264814.

About the Author(s)

Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as an Associate Editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

More Articles by Roisin McGuigan